Shatterproof Backs DEA Move to Schedule Kratom Derivative 7-OH

For years, products containing concentrated, semi-synthetic variants of kratom have been marketed as natural alternatives, despite carrying significant risks associated with opioid-like effects. Shatterproof leadership described the DEA’s move as a long-overdue intervention against the rapid proliferation of substances that have evaded standard regulatory scrutiny.

While the scheduling is a step toward greater oversight, the organization maintains that federal authorities must expand their focus to encompass the broader landscape of synthetic and highly concentrated kratom derivatives. Future policy efforts should prioritize establishing clear product standards, strengthening enforcement against misleading marketing, and funding rigorous scientific research. Shatterproof intends to keep advocating for evidence-based policies that restrict youth access to these emerging drugs while promoting transparency regarding the safety and efficacy of all kratom-related products.